These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32295157)

  • 41. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The safety of daratumumab for the treatment of multiple myeloma.
    Cejalvo MJ; Ribas P; de la Rubia J
    Expert Opin Drug Saf; 2017 Jun; 16(6):753-760. PubMed ID: 28490215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation.
    Willrich MA; Ladwig PM; Andreguetto BD; Barnidge DR; Murray DL; Katzmann JA; Snyder MR
    Clin Chem Lab Med; 2016 Jun; 54(6):1085-93. PubMed ID: 26812875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals.
    Youssef M; Arnesen C; Arledge C; Langley C; Sylvester D; Sikora J; Marques MB; Long Zheng X; Williams LA
    Transfus Apher Sci; 2019 Apr; 58(2):152-155. PubMed ID: 30639177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
    Vitkon R; Netanely D; Levi S; Ziv-Baran T; Ben-Yzak R; Katz BZ; Benyamini N; Trestman S; Mittelman M; Cohen Y; Avivi I
    Ther Adv Hematol; 2021; 12():20406207211035272. PubMed ID: 34377384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis.
    Menon T; Kataria S; Adhikari R; Khan H; Khalid MZ; Saeeduddin MO; Taj S; Rehman U; Tekin A; Singh R
    Cureus; 2021 May; 13(5):e15098. PubMed ID: 34155463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Challenges of Daratumumab in Transfusion Medicine.
    Dizon MF
    Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.
    Tang F; Malek E; Math S; Schmotzer CL; Beck RC
    Am J Clin Pathol; 2018 Jul; 150(2):121-129. PubMed ID: 29901687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.
    Jacobs JFM; Turner KA; Graziani MS; Frinack JL; Ettore MW; Tate JR; Booth RA; McCudden CR; Keren DF; Delgado JC; Zemtsovskaja G; Fullinfaw RO; Caldini A; de Malmanche T; Katakouzinos K; Burke M; Palladini G; Altinier S; Zaninotto M; Righetti G; Melki MT; Bell S; Willrich MAV
    Clin Chem Lab Med; 2020 Mar; 58(4):547-559. PubMed ID: 31940285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
    Ye Z; Wolf LA; Mettman D; Plapp FV
    Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting.
    Tam AH; Jung Y; Young R; Huang CY; Wolf J; Shah N; Wong SW; Martin TG; Lo M
    J Oncol Pharm Pract; 2022 Dec; 28(8):1819-1825. PubMed ID: 34647506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
    Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
    Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma.
    Cho N; Ko S; Shokeen M
    Oncotarget; 2021 Sep; 12(20):2039-2050. PubMed ID: 34611478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests.
    Zhou Y; Chen L; Jiang T; Fan L; Lei H; Wang Y; Heililahong H; Mi J; Du D; Miao T; Xia R; Wang X; Xiang D; Cai X; Tang X
    Hematology; 2021 Dec; 26(1):365-370. PubMed ID: 33971806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New developments in the treatment of multiple myeloma - clinical utility of daratumumab.
    McEllistrim C; Krawczyk J; O'Dwyer ME
    Biologics; 2017; 11():31-43. PubMed ID: 28442888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
    Soefje SA; Carpenter C; Carlson K; Awasthi S; Lin TS; Kaila S; Tarjan D; Kayal N; Kirkup C; Wagner TE; Gray KS; Kumar S
    JCO Oncol Pract; 2023 Apr; 19(4):e542-e549. PubMed ID: 36758192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.